Resumen
The Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS) assess the severity and disability caused by non-motor symptoms (NMS) in Parkinson's disease (PD).
This article encapsulates the formal process for completing this program and the data on the first officially approved non-English version of the MDS-NMS (Spanish).
The MDS-NMS translation program involves four steps: translation and back-translation; cognitive pre-testing to ensure that raters and patients understand the scale and are comfortable with its content; field testing of the finalized version; analysis of the factor structure of the tested version against the original English language version for the nine domains that could be analyzed in a confirmatory factor analysis. To be designated an “Official MDS translation,” the confirmatory factor analysis Comparative Fit Index had to be ≥0.90.
The Spanish MDS-NMS was tested in 364 native-Spanish-speaking patients with PD from seven countries. For all subjects with fully computable data with all domains of the MDS-NMS (n = 349), the Comparative Fit Index was ≥0.90 for the nine eligible domains. Missing data were negligible and moderate floor effect (42.90%) was found for the Non-Motor Fluctuations subscale. Item homogeneity coefficient was adequate, and the correlation of the MDS-NMS domains with other measures for related constructs was acceptable (rs ≥ 0.50).
The Spanish version of the MDS-NMS followed the IPMDS Translation Program protocol, reached the criterion to be designated as an Official Translation, and is now available on the MDS website.
| Idioma original | Inglés |
|---|---|
| Páginas (desde-hasta) | 586-595 |
| Número de páginas | 10 |
| Publicación | Movement Disorders Clinical Practice |
| Volumen | 10 |
| N.º | 4 |
| DOI | |
| Estado | Publicada - abr. 2023 |
Nota bibliográfica
Publisher Copyright:© 2023 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Financiación
| Financiadores | Número del financiador |
|---|---|
| Amneal and Adamas | |
| ISCIII‐FEDER | PI19/01576 |
| Instituto de Salud Carlos III‐Fondo Europeo de Desarrollo Regional | |
| MDS-NMS | |
| National Institutes of Health | |
| U.S. Department of Defense | |
| CHDI Foundation | |
| Teva Pharmaceutical Industries | |
| AbbVie | |
| Cleveland Clinic Foundation | |
| International Parkinson and Movement Disorder Society | |
| Sunovion | |
| “la Caixa” Foundation | |
| UCB | |
| Consejería de Transformación Económica, Industria, Conocimiento y Universidades | PY20_00903 |
| Ministerio de Economía y Competitividad | PI16/01575, PI19/0964 |
| Instituto de Salud Carlos III | |
| Ministerio de Ciencia e Innovación | RTC2019‐007150‐ 1 |
| Horizon 2020 | |
| Consejería de Salud y Familias, Junta de Andalucía | PE‐0210‐2018 |